Jean Pierre Delord - JoVE Visualize

Showing results (131-140 of 178) with videos related to

Pageof 18

Sort By:

JAMA Oncology|November 8, 2019

Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical TrialKimberley M Heinhuis, Matteo Carlino, Markus Joerger, et al.

Science Translational Medicine|January 24, 2024

The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancersAurélien Voissière, Carlos Gomez-Roca, Sylvie Chabaud, et al.

European Journal of Cancer (Oxford, England : 1990)|March 17, 2017

A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU studyAlain Ravaud, Christelle de la Fouchardière, Philippe Caron, et al.

JCI Insight|December 17, 2020

PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cellsCamille-Charlotte Balança, Anna Salvioni, Clara-Maria Scarlata, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 6, 2019

Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 TrialR Wendel Naumann, Antoine Hollebecque, Tim Meyer, et al.

International Journal of Cancer|June 20, 2025

Sizing and concentration analysis of cfDNA using Biabooster technology: Results from a prospective plasma-based collection of 77 patients with locally advanced unresectable esophageal cancerAnouchka Modesto, Sophie Gibert, Caroline Delmas, et al.

European Journal of Cancer (Oxford, England : 1990)|July 28, 2023

Phase Ib/II trial of tipapkinogene sovacivec, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16-positive cancersEdith Borcoman, Ana Lalanne, Jean-Pierre Delord, et al.

JAMA Oncology|November 2, 2018

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical TrialLillian L Siu, Caroline Even, Ricard Mesía, et al.

Targeted Oncology|October 24, 2023

A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaAlbiruni R Abdul Razak, Hung-Ming Wang, Jang-Yang Chang, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 24, 2016

A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung CancerDavid R Gandara, Natasha Leighl, Jean-Pierre Delord, et al.

Pageof 18

Showing results (131-140 of 178) with videos related to

Sort By:

Pageof 18

JAMA Oncology|November 8, 2019

Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical TrialKimberley M Heinhuis, Matteo Carlino, Markus Joerger, et al.

Science Translational Medicine|January 24, 2024

The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancersAurélien Voissière, Carlos Gomez-Roca, Sylvie Chabaud, et al.

European Journal of Cancer (Oxford, England : 1990)|March 17, 2017

A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU studyAlain Ravaud, Christelle de la Fouchardière, Philippe Caron, et al.

JCI Insight|December 17, 2020

PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cellsCamille-Charlotte Balança, Anna Salvioni, Clara-Maria Scarlata, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 6, 2019

Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 TrialR Wendel Naumann, Antoine Hollebecque, Tim Meyer, et al.

International Journal of Cancer|June 20, 2025

Sizing and concentration analysis of cfDNA using Biabooster technology: Results from a prospective plasma-based collection of 77 patients with locally advanced unresectable esophageal cancerAnouchka Modesto, Sophie Gibert, Caroline Delmas, et al.

European Journal of Cancer (Oxford, England : 1990)|July 28, 2023

Phase Ib/II trial of tipapkinogene sovacivec, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16-positive cancersEdith Borcoman, Ana Lalanne, Jean-Pierre Delord, et al.

JAMA Oncology|November 2, 2018

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical TrialLillian L Siu, Caroline Even, Ricard Mesía, et al.

Targeted Oncology|October 24, 2023

A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaAlbiruni R Abdul Razak, Hung-Ming Wang, Jang-Yang Chang, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 24, 2016

A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung CancerDavid R Gandara, Natasha Leighl, Jean-Pierre Delord, et al.

Pageof 18